Author + information
- Received February 20, 2004
- Revision received April 10, 2004
- Accepted April 27, 2004
- Published online August 18, 2004.
- Nicholas Kipshidze, MD, PhD, FACC*,* (, )
- George Dangas, MD, PhD, FACC*,
- Mykola Tsapenko, MD, PhD§,
- Jeffrey Moses, MD, FACC*,
- Martin B. Leon, MD, FACC*,
- Michael Kutryk, MD† and
- Patrick Serruys, MD, PhD, FACC‡
- ↵*Reprint requests and correspondence:
Dr. Nicholas Kipshidze, Lenox Hill Heart and Vascular Institute, 130 East 77th Street, New York, New York 10021
Restenosis at the site of an endoluminal procedure remains a significant problem in the practice of interventional cardiology. We present current data on intimal hyperplasia, which identify the major role of endothelial cells (ECs) in the development of restenosis. Considering endothelial denudation as one of the most important mechanisms contributing to restenosis, we focus more attention on methods of accelerating restoration of endothelial continuity. Prevention of restenosis may be achieved by promoting endothelial regeneration through the use of growth factors, EC seeding, vessel reconstruction with autologous EC/fibrin matrix, and the use of estrogen-loaded stents and stents designed to capture progenitor ECs.
Dr. Kipshidze is a consultant to AVI-Biopharma and a major stockholder in EVT. Dr. Dangas is a consultant to Cordis and Guidant, receives research grant support from Cordis and Boston Scientific, and receives speaker honoraria from Cordis. Dr. Kutryk is a consultant and Drs. Serruys and Leon are scientific advisers to Orbus Medical Technologies. Drs. Leon and Moses receive honoraria for speaking engagements from and have common stock holdings in Cordis, a Johnson & Johnson Company.
- Received February 20, 2004.
- Revision received April 10, 2004.
- Accepted April 27, 2004.
- American College of Cardiology Foundation